Arcus Biosciences Investor Event - ARCUS BIOSCIENCES INC

Explicit Guidance:

• Peak 20 (First Line): Enrollment expected to begin "at the end of this year" for the registrational trial combining Casdatafan (CAS) + anti-PD-1 (+/- IPI); primary endpoint is PFS.
• Peak 1 (Second Line): Fully enrolled by "the end of this year"; primary endpoint is PFS with full statistical power recycled to assess Overall Survival (OS).
• Late-Line (Third Line): Enrollment has begun for an ARC-20 randomized arm (CAS + Tevo vs. Tevo); a Phase 3 trial is in "work to enable" stage.
• Commercial Opportunity: Management projects a "$5 to $10 billion commercial opportunity" for Casdatafan, with specific mention of a "$4 billion plus commercial opportunity" in the frontline and a "$2 billion opportunity" in the second line.
• Safety Data: Triplet safety data (CAS + Nevo + Ipi) is already complete and "packaged up, ready to go" to FDA/EMA to initiate Phase 3.
• Dose Potency: Even at reduced doses (50mg), Casdatafan is stated to be a "more potent HIF-2 inhibitor than the commercial dose (120mg) of Belzutafan."

Business-Segment Outlook:

• First Line: Targeting Ipi-nevo (30% market share) by reducing the 20% primary progression rate; expected to become the dominant regimen with a 50% ORR (up from ~30% for Ipi-nevo) and 69% landmark PFS at 12 months vs. 50% for Ipi-nevo.
• Second Line: Targeting Cabozantinib (40% regimen share, 80% monotherapy) with CAS-CABO; aiming to improve upon the 14-month PFS of late-line monotherapy and the 8-10 month PFS of TKI monotherapy benchmarks.
• Late Line: Targeting Tivozanib (Tevo) and monotherapy options (Belzutafan/Tivozanib); aiming to replace monotherapy use with CAS-Tevo to improve PFS and OS.
• Pipeline Expansion: Developing combinations with axitinib (AXI) and VEGF/VEGF bispecifics (partnerships with BMS, Pfizer, Summit) in the first line.
• Long-term Utilization: Anticipating patients to remain on Casdatafan-based regimens for "5 to 10 years, hopefully plus 10 plus years," creating a "backbone therapy" similar to bevacizumab in colorectal cancer.

Market and Competitive Outlook:

• vs. Belzutafan: Positions Casdatafan as "best-in-class" HIF-2 inhibitor, offering superior durability (EPO suppression >84% sustained vs. Belzutafan's 64% waning after ~3 months) and overcoming prior TKI-induced HIF-2 upregulation.
• vs. TKI Monotherapy: Projects CAS monotherapy disease control comparable to TKIs without "TKI baggage" (toxicity, QoL impact).
• vs. LightSpark 011 (Lenva+Bels): Expects to achieve a statistically significant OS benefit in Phase 3 (Peak 1) by outperforming the Bels-Lenva HR of 0.85, leveraging a control arm (Cabozantinib) that includes heavy TKI-pretreated populations expected to perform worse than historical benchmarks.
• Market Share: Anticipates shifting physician preference from Lenva-Bels in second line back to Cabozantinib monotherapy or CAS-CABO, citing physician comfort with Cabozantinib's historical Phase 3 data.

Macro / Industry Outlook:

• Regulatory Pathway: Safety data for the frontline triplet is already meeting FDA/EMA specifications for study initiation; enrollment speed expected to be rapid ("enroll gangbusters").
• Economic Factors: Management notes that while Belzutafan/Lenva are approved, reimbursement/access issues (particularly for Lenva outside the US) may influence sequencing decisions in global trials.

Strategic Initiatives:

• Clinical Development:
  • Peak 20 (Frontline): Combining CAS with Nevo (+/- Ipi) to create a TKI-sparing regimen; aiming to eliminate the 20% primary progression rate of Ipi-nevo.
  • Peak 1 (Second Line): CAS-CABO vs. CABO; designed to capture the "underserved" 60% of patients previously treated with 2nd-gen TKIs (Axie/Lenva).
  • Late Line: CAS-Tevo to replace monotherapy options; randomized arm in ARC-20 enrolling prior HIF-2 users.
• Partnerships: Collaborations with BMS, Pfizer, and Summit to test VEGF/VEGF bispecifics with Casdatafan in the first line.
• Scientific Validation: Publishing Nature paper correlations between HIF-2 inhibition (EPO/PI-1 reduction) and clinical outcomes (ORR, PFS, OS).

Risks and Headwinds to Outlook:

• Primary Progression: Residual ~7-11% rate of primary progression in combination cohorts (down from 20% with Ipi-nevo) remains a key metric to manage.
• Toxicity Management: Expected anemia and hypoxia (on-target HIF-2 effects) will require monitoring; potential for dose reductions (to 50mg) though potency remains high.
• Control Arm Performance: Potential for the Cabozantinib control arm in Peak 1 to underperform historical benchmarks due to high prevalence of prior 2nd-gen TKI exposure, which could mask treatment effects if not accounted for.
• Biomarker Variability: ~15-20% of tumors may have low HIF-2 alpha activity; however, management asserts Casdatafan still provides benefit to these patients compared to competitors.

Management Tone on the Future:

• High Confidence: Describes the molecule as "hands down, the best molecule... bar none" and "a grand slammer."
• Aggressive Outlook: Expects curves to "dramatically separate" over time; confident in hitting OS endpoints in second line and PFS in first line.
• Strategic Certainty: Emphasizes "zero evidence of any meaningful resistance development," supporting long-term backbone therapy.
• Tolerance for Hurdles: Acknowledges the "Achilles heel" of previous triplet failures (toxicity overlap) but views Casdatafan's orthogonal toxicity profile as a decisive advantage.